JOP20190152A1 - مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة - Google Patents
مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلةInfo
- Publication number
- JOP20190152A1 JOP20190152A1 JOP/2019/0152A JOP20190152A JOP20190152A1 JO P20190152 A1 JOP20190152 A1 JO P20190152A1 JO P20190152 A JOP20190152 A JO P20190152A JO P20190152 A1 JOP20190152 A1 JO P20190152A1
- Authority
- JO
- Jordan
- Prior art keywords
- activin
- myostatin
- treatment
- obesity
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
Abstract
يتعلق الاختراع الحالي بمضادات ميوستاتين أو آكتيفين أو مضادات مستقبل للاستخدام في تحسين تركيبة الجسم، مثلا، لعلاج البدانة المركزية، السمنة أو حالة زيادة الوزن والأمراض المصاحبة ذات الصلة. يتعلق الاختراع الحالي بمضادات ميوستاتين أو آكتيفين أو مضادات مستقبل لعلاج السكري من النوع II بواسطة تحسين التحكم في سكر الدم، تحديدا بواسطة زيادة حساسية الإنسولين. الشكل 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662437097P | 2016-12-21 | 2016-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20190152A1 true JOP20190152A1 (ar) | 2019-06-20 |
Family
ID=60972283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2019/0152A JOP20190152A1 (ar) | 2016-12-21 | 2017-06-16 | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20190345251A1 (ar) |
| EP (2) | EP3558361B1 (ar) |
| JP (2) | JP7280825B2 (ar) |
| KR (2) | KR20190097138A (ar) |
| CN (2) | CN110087684B (ar) |
| AU (1) | AU2017380844B2 (ar) |
| BR (1) | BR112019012661A2 (ar) |
| CA (1) | CA3042965A1 (ar) |
| CL (1) | CL2019001683A1 (ar) |
| DK (1) | DK3558361T3 (ar) |
| ES (1) | ES3048908T3 (ar) |
| FI (1) | FI3558361T3 (ar) |
| HR (1) | HRP20251338T1 (ar) |
| IL (1) | IL267471B1 (ar) |
| JO (1) | JOP20190152A1 (ar) |
| LT (1) | LT3558361T (ar) |
| MX (2) | MX2019007581A (ar) |
| PH (1) | PH12019501026A1 (ar) |
| PL (1) | PL3558361T3 (ar) |
| PT (1) | PT3558361T (ar) |
| RS (1) | RS67393B1 (ar) |
| SI (1) | SI3558361T1 (ar) |
| TW (2) | TWI812606B (ar) |
| WO (1) | WO2018116201A1 (ar) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3215175A4 (en) | 2014-11-06 | 2018-06-27 | Scholar Rock, Inc. | Anti-pro/latent-myostatin antibodies and uses thereof |
| HRP20211081T1 (hr) | 2015-09-15 | 2021-10-15 | Scholar Rock, Inc. | Anti-pro/latentna miostatinska protutijela i njihove uporabe |
| CN115814077A (zh) | 2016-01-08 | 2023-03-21 | 供石公司 | 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法 |
| NZ789269A (en) | 2016-06-13 | 2026-01-30 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
| TWI795381B (zh) | 2016-12-21 | 2023-03-11 | 比利時商健生藥品公司 | 作為ｍａｌｔ１抑制劑之吡唑衍生物 |
| EP4218817A3 (en) | 2017-01-06 | 2023-09-06 | Scholar Rock, Inc. | Methods for treating metabolic diseases by inhibiting myostatin activation |
| GB201706857D0 (en) * | 2017-04-28 | 2017-06-14 | Select Res Ltd | Health risk prediction tools |
| AU2019289222B2 (en) | 2018-06-18 | 2023-07-13 | Janssen Pharmaceutica Nv | Pyrazole derivatives as MALT1 inhibitors |
| EP3953345B1 (en) | 2019-04-11 | 2023-04-05 | Janssen Pharmaceutica NV | Pyridine rings containing derivatives as malt1 inhibitors |
| CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| US20230174620A1 (en) | 2020-04-28 | 2023-06-08 | Acceleron Pharma Inc. | Actrii proteins and use in treating post-capillary pulmonary hypertension |
| WO2022221291A2 (en) * | 2021-04-12 | 2022-10-20 | University Of Florida Research Foundation Incorporated | Compositions and methods for treating obesity |
| CA3221555A1 (en) * | 2021-06-23 | 2022-12-29 | Kimberly LONG | A myostatin pathway inhibitor in combination with a glp-1 pathway activator for use in treating metabolic disorders |
| KR20240099142A (ko) | 2021-08-27 | 2024-06-28 | 버사니스 바이오, 인크. | 병용 요법 |
| TW202339798A (zh) * | 2022-01-19 | 2023-10-16 | 美商維紗妮絲生物公司 | Actrii抗體之治療 |
| JP2025529933A (ja) | 2022-08-26 | 2025-09-09 | バーサニス・バイオ・インコーポレイテッド | ＡｃｔＲＩＩ抗体固定単位用量の治療 |
| EP4638496A1 (en) | 2022-12-22 | 2025-10-29 | Scholar Rock, Inc. | Selective and potent inhibitory antibodies of myostatin activation |
| WO2025027052A1 (en) | 2023-07-31 | 2025-02-06 | Sixpeaks Bio Ag | Antibody conjugates and fusion proteins |
| WO2025183966A1 (en) | 2024-02-28 | 2025-09-04 | Versanis Bio, Inc. | Actrii antibodies with extended half life |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20120532A1 (es) | 2009-04-27 | 2012-05-18 | Novartis Ag | ANTICUERPOS ANTI-ActRIIB |
| KR20120049214A (ko) * | 2009-06-08 | 2012-05-16 | 악셀레론 파마 인코포레이티드 | 발열성 지방세포를 증가시키는 방법 |
| KR20180026795A (ko) * | 2009-06-12 | 2018-03-13 | 악셀레론 파마 인코포레이티드 | 절두된 ＡｃｔＲＩＩＢ-ＦＣ 융합 단백질 |
| EP3202459B1 (en) * | 2009-09-09 | 2021-04-14 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof for treating obesity or type 2 diabetes by regulating body fat content |
| JP6472999B2 (ja) * | 2011-07-01 | 2019-02-20 | ノバルティス アーゲー | 代謝障害を治療するための方法 |
| NZ703724A (en) * | 2012-06-11 | 2017-06-30 | Amgen Inc | Dual receptor antagonistic antigen-binding proteins and uses thereof |
| TN2017000217A1 (en) * | 2014-12-08 | 2018-10-19 | Novartis Ag | Myostatin or activin antagonists for the treatment of sarcopenia |
| WO2016205370A1 (en) * | 2015-06-15 | 2016-12-22 | Santa Maria Biotherapeutics, Inc. | Methods of using activin receptor iib-based proteins |
| CA3001654A1 (en) * | 2015-11-11 | 2017-05-18 | Novartis Ag | Uses of myostatin antagonists, combinations containing them and uses thereof |
-
2017
- 2017-06-16 JO JOP/2019/0152A patent/JOP20190152A1/ar unknown
- 2017-12-20 EP EP17829315.5A patent/EP3558361B1/en active Active
- 2017-12-20 MX MX2019007581A patent/MX2019007581A/es unknown
- 2017-12-20 BR BR112019012661-9A patent/BR112019012661A2/pt unknown
- 2017-12-20 DK DK17829315.5T patent/DK3558361T3/da active
- 2017-12-20 CA CA3042965A patent/CA3042965A1/en active Pending
- 2017-12-20 KR KR1020197020340A patent/KR20190097138A/ko not_active Ceased
- 2017-12-20 IL IL267471A patent/IL267471B1/en unknown
- 2017-12-20 SI SI201731631T patent/SI3558361T1/sl unknown
- 2017-12-20 EP EP25196508.3A patent/EP4659804A3/en active Pending
- 2017-12-20 WO PCT/IB2017/058199 patent/WO2018116201A1/en not_active Ceased
- 2017-12-20 FI FIEP17829315.5T patent/FI3558361T3/fi active
- 2017-12-20 JP JP2019533642A patent/JP7280825B2/ja active Active
- 2017-12-20 KR KR1020247032712A patent/KR20240147705A/ko active Pending
- 2017-12-20 ES ES17829315T patent/ES3048908T3/es active Active
- 2017-12-20 PL PL17829315.5T patent/PL3558361T3/pl unknown
- 2017-12-20 CN CN201780078980.9A patent/CN110087684B/zh active Active
- 2017-12-20 US US16/471,756 patent/US20190345251A1/en not_active Abandoned
- 2017-12-20 LT LTEPPCT/IB2017/058199T patent/LT3558361T/lt unknown
- 2017-12-20 RS RS20251104A patent/RS67393B1/sr unknown
- 2017-12-20 PT PT178293155T patent/PT3558361T/pt unknown
- 2017-12-20 AU AU2017380844A patent/AU2017380844B2/en active Active
- 2017-12-20 CN CN202311527567.XA patent/CN118105478A/zh active Pending
- 2017-12-20 HR HRP20251338TT patent/HRP20251338T1/hr unknown
- 2017-12-21 TW TW106144972A patent/TWI812606B/zh active
- 2017-12-21 TW TW112127021A patent/TWI848773B/zh active
-
2019
- 2019-05-09 PH PH12019501026A patent/PH12019501026A1/en unknown
- 2019-06-19 CL CL2019001683A patent/CL2019001683A1/es unknown
- 2019-06-21 MX MX2024001135A patent/MX2024001135A/es unknown
-
2021
- 2021-03-02 US US17/190,356 patent/US20210363263A1/en not_active Abandoned
-
2022
- 2022-12-22 JP JP2022205197A patent/JP7843223B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20190152A1 (ar) | مضادات الميوستاتين، الآكتيفين أو مستقبلات الآكتيفين للاستخدام في علاج السمنة والحالات ذات الصلة | |
| CY1119987T1 (el) | Παραγωγα εξενδινης-4 ως διττοι αγωνιστες glp1/γλυκαγονης | |
| BR112015018104A2 (pt) | polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições | |
| PH12019501216A1 (en) | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists | |
| MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
| TW201613633A (en) | Exendin-4 derivatives as selective glucagon receptor agonists | |
| MX362190B (es) | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon. | |
| MX2019006427A (es) | Nuevos compuestos como agonistas peptidicos de receptores de glp1/glucagon/gip. | |
| EA201590294A1 (ru) | Аналоги глюкагона | |
| MX368435B (es) | Analogos del glucagon. | |
| BR112016029713A8 (pt) | uso de uma carboximetilcelulose reticulada e uso de um agente gelificante | |
| PH12014501336A1 (en) | Glucagon analogues | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| CL2014002556A1 (es) | Compuestos derivados de ácidos indaniloxidihidrobenzofuranilacéticos, agonistas del receptor gpr40; composiicon farmaceutica; y su uso en el tratamiento de enfermedades o afecciones como diabetes, resistencia a la insulina, obesidad, entre otras. | |
| MX2016013033A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados. | |
| CL2014000458A1 (es) | Compuestos derivados de 2-amino-4-(piridin-2-il)-5,6-dihidro-4h-1,3-oxazina; composicion y combinacion farmaceutica; y uso en el tratamiento o en la prevencion del alzheimer, diabetes tipo 2, obesidad, entre otras enfermedades. | |
| EA201791611A1 (ru) | Лечение пациентов детского возраста с сахарным диабетом 2 типа с помощью ликсисенатида | |
| MX2015008555A (es) | Combinaciones de un agonista de glp1r y metformina, y uso de los mismos para el tratamiento de la diabetes tipo 2 y otros trastornos. | |
| PH12017500084A1 (en) | Vitamin b2 and its use | |
| BR112017005986A2 (pt) | composições e métodos de uso para o tratamento de distúrbios metabólicos |